MelNet Advocacy and Submissions

One of MelNet's roles is to be the voice of health professionals working in melanoma in New Zealand.  As part of this role the Executive Committee works alongside members and partner organisations to write letters and submissions.  Some of these are available below.

Joint response from MelNet, Melanoma New Zealand and Cancer Society of New Zealand on PHARMAC proposal to amend Nivolumab (Opdivo) and pembrolizumab (Keytruda) funding criteria